Login
Navigate Fool.com
Will RARE beat
the market?

ULTRAGENYX PHARMAC

NASDAQ: RARE

Community Rating: 2 Stars: Unattractive

42.56 -2.66 (-5.88%)

Quote as of

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $44.87
Previous Close $45.22
Daily Range $42.00 - $44.87
52-Week Range $35.15 - $69.77
Market Cap $1.3B
P/E Ratio -2.86
Dividend (Yield) $0.00 (0.0%)
Volume 410,142
Average Daily Volume 229,112
Current FY EPS -$1.80

How do you think RARE
will perform against the market?

Top RARE Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

Biotechs Tripling at IPO! Sign of Biotech Bubble?

Investors are craving the risk that's offered by the IPOs of Ultragenyx Pharmaceuticals and Dicerna Pharmaceuticals.

Healthcare Stocks Large Drag on Markets Today; Ultragenyx Pharma Tumbles After Q4 Net Loss Widens

Sector Update: Healthcare

US IPO Recap: Varonis provides data security for enterprises and financial security for investors

Stocks: Insiders Buy at 4 Biotechs -- Dicerna, Ultragenyx, Regulus, and Cara

Regulus Therapeutics renewed its strategic alliance with French pharmaceutical company Sanofi, which added $10 million in equity to its stake in the firm.

Biotechs dominate IPO calendar, but most post negative returns

US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs

See More RARE News...

Sector

Industry

ULTRAGENYX PHARMAC (RARE) Description

ULTRAGENYX PHARMAC Website: http://www.ultragenyx.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks